Because a number of metabolic diseases, including type-2 diabetes and insulin resistance, are closely related to the chronic inflammatory response, these pharmacological functions of GPR120 have recently encouraged many pharmaceutical companies to choose GRP120 as a novel target for the treatment of metabolic diseases [2,7]. Here, FFAR4 is linked to Other metabolic disease.